Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more
Can Fite Biopharma Ltd (CANF) - Total Liabilities
Latest total liabilities as of June 2025: ILA3.54 Million ILA
Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has total liabilities worth ILA3.54 Million ILA as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Can Fite Biopharma Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how Can Fite Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Can Fite Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Can Fite Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CF Acquisition Corp. VII Warrant
NASDAQ:CFFSW
|
USA | $12.74 Million |
|
Kuchai Develop Bhd
KLSE:2186
|
Malaysia | RM1.73 Million |
|
WUESTENROT & WUERTT
BE:WUW
|
Germany | €67.71 Billion |
|
GUESS? (GU9.SG)
STU:GU9
|
Germany | €2.24 Billion |
|
Picpay Holdings Netherlands N.V. Class A Common Shares
NASDAQ:PICS
|
USA | $34.71 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Can Fite Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Can Fite Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Can Fite Biopharma Ltd (2003–2024)
The table below shows the annual total liabilities of Can Fite Biopharma Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA3.68 Million | -1.66% |
| 2023-12-31 | ILA3.75 Million | -22.14% |
| 2022-12-31 | ILA4.81 Million | -18.05% |
| 2021-12-31 | ILA5.87 Million | +70.22% |
| 2020-12-31 | ILA3.45 Million | -39.83% |
| 2019-12-31 | ILA5.73 Million | +16.10% |
| 2018-12-31 | ILA4.94 Million | +3.32% |
| 2017-12-31 | ILA4.78 Million | -24.07% |
| 2016-12-31 | ILA6.29 Million | -12.06% |
| 2015-12-31 | ILA7.16 Million | +114.89% |
| 2014-12-31 | ILA3.33 Million | +52.99% |
| 2013-12-31 | ILA2.18 Million | -7.11% |
| 2012-12-31 | ILA2.34 Million | +45.41% |
| 2011-12-31 | ILA1.61 Million | -70.56% |
| 2010-12-31 | ILA5.47 Million | -17.25% |
| 2009-12-31 | ILA6.62 Million | -6.41% |
| 2008-12-31 | ILA7.07 Million | -30.92% |
| 2007-12-31 | ILA10.23 Million | +199.06% |
| 2006-12-31 | ILA3.42 Million | +171.94% |
| 2005-12-31 | ILA1.26 Million | -59.25% |
| 2004-12-31 | ILA3.09 Million | +380.84% |
| 2003-12-31 | ILA642.00K | -- |